These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
148 related articles for article (PubMed ID: 12821933)
21. Role of the von Hippel-Lindau tumour suppressor protein in the regulation of HIF-1alpha and its oxygen-regulated transactivation domains at high cell density. Paltoglou SM; Roberts BJ Oncogene; 2005 May; 24(23):3830-5. PubMed ID: 15750626 [TBL] [Abstract][Full Text] [Related]
22. Loss of von Hippel-Lindau protein causes cell density dependent deregulation of CyclinD1 expression through hypoxia-inducible factor. Baba M; Hirai S; Yamada-Okabe H; Hamada K; Tabuchi H; Kobayashi K; Kondo K; Yoshida M; Yamashita A; Kishida T; Nakaigawa N; Nagashima Y; Kubota Y; Yao M; Ohno S Oncogene; 2003 May; 22(18):2728-38. PubMed ID: 12743597 [TBL] [Abstract][Full Text] [Related]
23. Mechanism of regulation of the hypoxia-inducible factor-1 alpha by the von Hippel-Lindau tumor suppressor protein. Tanimoto K; Makino Y; Pereira T; Poellinger L EMBO J; 2000 Aug; 19(16):4298-309. PubMed ID: 10944113 [TBL] [Abstract][Full Text] [Related]
24. Requirement for the von Hippel-Lindau tumor suppressor gene for functional epidermal growth factor receptor blockade by monoclonal antibody C225 in renal cell carcinoma. Perera AD; Kleymenova EV; Walker CL Clin Cancer Res; 2000 Apr; 6(4):1518-23. PubMed ID: 10778984 [TBL] [Abstract][Full Text] [Related]
25. Specific oncolytic effect of a new hypoxia-inducible factor-dependent replicative adenovirus on von Hippel-Lindau-defective renal cell carcinomas. Cuevas Y; Hernández-Alcoceba R; Aragones J; Naranjo-Suárez S; Castellanos MC; Esteban MA; Martín-Puig S; Landazuri MO; del Peso L Cancer Res; 2003 Oct; 63(20):6877-84. PubMed ID: 14583486 [TBL] [Abstract][Full Text] [Related]
26. Identification of membrane type-1 matrix metalloproteinase as a target of hypoxia-inducible factor-2 alpha in von Hippel-Lindau renal cell carcinoma. Petrella BL; Lohi J; Brinckerhoff CE Oncogene; 2005 Feb; 24(6):1043-52. PubMed ID: 15592504 [TBL] [Abstract][Full Text] [Related]
27. The von Hippel-Lindau protein interacts with heteronuclear ribonucleoprotein a2 and regulates its expression. Pioli PA; Rigby WF J Biol Chem; 2001 Oct; 276(43):40346-52. PubMed ID: 11517223 [TBL] [Abstract][Full Text] [Related]
28. Hypoxia upregulates von Hippel-Lindau tumor-suppressor protein through RhoA-dependent activity in renal cell carcinoma. Turcotte S; Desrosiers RR; Beliveau R Am J Physiol Renal Physiol; 2004 Feb; 286(2):F338-48. PubMed ID: 14583436 [TBL] [Abstract][Full Text] [Related]
29. Effects of ras and von Hippel-Lindau (VHL) gene mutations on hypoxia-inducible factor (HIF)-1alpha, HIF-2alpha, and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol 3'-kinase/Akt signaling pathway. Blancher C; Moore JW; Robertson N; Harris AL Cancer Res; 2001 Oct; 61(19):7349-55. PubMed ID: 11585776 [TBL] [Abstract][Full Text] [Related]
30. Protective function of von Hippel-Lindau protein against impaired protein processing in renal carcinoma cells. Gorospe M; Egan JM; Zbar B; Lerman M; Geil L; Kuzmin I; Holbrook NJ Mol Cell Biol; 1999 Feb; 19(2):1289-300. PubMed ID: 9891063 [TBL] [Abstract][Full Text] [Related]
31. Endoplasmic reticulum/cytosolic localization of von Hippel-Lindau gene products is mediated by a 64-amino acid region. Schoenfeld AR; Davidowitz EJ; Burk RD Int J Cancer; 2001 Feb; 91(4):457-67. PubMed ID: 11251966 [TBL] [Abstract][Full Text] [Related]
32. Expression of the angiopoietins and their receptor Tie2 in human renal clear cell carcinomas; regulation by the von Hippel-Lindau gene and hypoxia. Currie MJ; Gunningham SP; Turner K; Han C; Scott PA; Robinson BA; Chong W; Harris AL; Fox SB J Pathol; 2002 Dec; 198(4):502-10. PubMed ID: 12434420 [TBL] [Abstract][Full Text] [Related]
33. Silencing of epidermal growth factor receptor suppresses hypoxia-inducible factor-2-driven VHL-/- renal cancer. Smith K; Gunaratnam L; Morley M; Franovic A; Mekhail K; Lee S Cancer Res; 2005 Jun; 65(12):5221-30. PubMed ID: 15958567 [TBL] [Abstract][Full Text] [Related]
34. Role of transforming growth factor-alpha in von Hippel--Lindau (VHL)(-/-) clear cell renal carcinoma cell proliferation: a possible mechanism coupling VHL tumor suppressor inactivation and tumorigenesis. de Paulsen N; Brychzy A; Fournier MC; Klausner RD; Gnarra JR; Pause A; Lee S Proc Natl Acad Sci U S A; 2001 Feb; 98(4):1387-92. PubMed ID: 11171960 [TBL] [Abstract][Full Text] [Related]
35. The von Hippel-Lindau tumor suppressor targets to mitochondria. Shiao YH; Resau JH; Nagashima K; Anderson LM; Ramakrishna G Cancer Res; 2000 Jun; 60(11):2816-9. PubMed ID: 10850420 [TBL] [Abstract][Full Text] [Related]